Nivolumab associated vasculopathy: A novel mechanism.

Haroon, Adeeb; Parker, James K; Braudis, Kara; Smith, Emily H

Haroon, Adeeb; Parker, James K; Braudis, Kara; Smith, Emily H.

Afiliação

Haroon A; Department of Dermatology, University of Missouri, Columbia, Missouri.
Parker JK; Department of Dermatology, University of Missouri, Columbia, Missouri.
Braudis K; Department of Dermatology, University of Missouri, Columbia, Missouri.
Smith EH; Department of Dermatology, University of Missouri, Columbia, Missouri.

JAAD Case Rep ; 22: 8-10, 2022 Apr.

Article em En | MEDLINE | ID: mdl-35265738

Palavras-chave

CTLA-4, cytotoxic T-lymphocyte antigen-4; ICI(s), immune checkpoint inhibitor(s); PD-1, programmed cell death protein 1 (PD-1) or its ligand (PD-L1); immune-related adverse event; irAE(s), immune-related adverse event(s); nivolumab; vasculopathy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: JAAD Case Rep Ano de publicação: 2022 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google